QQ客服 官方微博 反馈留言

浏览/检索结果: 共8条，第1-8条 帮助 限定条件 专题：上海药物研究所    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance 期刊论文 MOLECULAR CANCER, 2020, 卷号: 19, 期号: 1, 页码: 15 作者:  Zhang, Tao;  Qu, Rong;  Chan, Shingpan;  Lai, Mengzhen;  Tong, Linjiang 收藏  |  浏览/下载：43/0  |  提交时间：2020/07/01 Non-small cell lung cancer (NSCLC)  EGFR T790M  Small-molecule inhibitor  Drug resistance  Ack1   Inhibition of Tumor Lymphangiogenesis is an Important Part that EGFR-TKIs Play in the Treatment of NSCLC 期刊论文 JOURNAL OF CANCER, 2020, 卷号: 11, 期号: 1, 页码: 241-250 作者:  Zhang, Yan;  Yang, Xinying;  Liu, Hongchun;  Cai, Minghui;  Yang Shentu 收藏  |  浏览/下载：32/0  |  提交时间：2020/07/01 EGFR-TKIs  NSCLC  lymphangiogenesis  JAK/STAT3  LYVE-1   SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met 期刊论文 CANCER SCIENCE, 2019, 页码: 11 作者:  Tong, Mengya;  Gao, Mingzhao;  Xu, Yongping;  Fu, Li;  Li, Yun 收藏  |  浏览/下载：23/0  |  提交时间：2020/07/01 AZD9291  c-Met ADC  c-Met overexpression  resistance  SHR-A1403   Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer 期刊论文 CELL DEATH & DISEASE, 2018, 卷号: 9 作者:  Mao, Jianhua;  Ma, Lie;  Shen, Yan;  Zhu, Kongkai;  Zhang, Ru 收藏  |  浏览/下载：50/0  |  提交时间：2019/01/08 Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells 期刊论文 ACTA PHARMACOLOGICA SINICA, 2016, 卷号: 37, 期号: 12, 页码: 1587-1596 作者:  Wang, Yue-qin;  Shen, Ai-jun;  Sun, Jing-ya;  Wang, Xin;  Liu, Hong-chun 收藏  |  浏览/下载：33/0  |  提交时间：2019/01/08 non-small cell lung cancer  gefitinib resistance  Hsp90   targetinghsp90withfs108circumventsgefitinlbresistanceinegfrmutantnonsmallcelllungcancercells 期刊论文 actapharmacologicasinica, 2016, 卷号: 37, 期号: 12, 页码: 1587 作者:  Wang Yueqin;  Shen Aijun;  Sun Jingya;  Wang Xin;  Liu Hongchun 收藏  |  浏览/下载：1/0  |  提交时间：2020/07/01 non-small cell lung cancer  gefitinlb resistance  Hsp90   Targeting Hsp90 with FS-108 circumvents gefitinlb resistance in EGFR mutant non-small cell lung cancer cells 期刊论文 Acta Pharmacologica Sinica, 2016, 卷号: 37, 期号: 12, 页码: 1587 作者:  Wang Yueqin;  Shen Aijun;  Sun Jingya;  Wang Xin;  Liu Hongchun 收藏  |  浏览/下载：14/0  |  提交时间：2020/12/24 non-small cell lung cancer  gefitinlb resistance  Hsp90   DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro 期刊论文 ACTA PHARMACOLOGICA SINICA, 2015, 卷号: 36, 期号: 10, 页码: 1266-1276 作者:  Guo, Xiao-bin;  Zhu, Wei;  Chen, Xian-jie;  Tong, Lin-jiang;  Peng, Xia 收藏  |  浏览/下载：39/0  |  提交时间：2019/01/08 DCLAK11  substituted pyridin-3-amine derivatives  tyrosine kinase  EGFR  HER2  VEGFR2  anticancer  anti-angiogenesis